SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-20-317577
Filing Date
2020-12-15
Accepted
2020-12-15 08:22:54
Documents
12
Period of Report
2020-12-10
Items
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

Document Format Files

Seq Description Document Type Size
1 8-K d33739d8k.htm   iXBRL 8-K 25433
  Complete submission text file 0001193125-20-317577.txt   144014

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA akba-20201210.xsd EX-101.SCH 3052
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE akba-20201210_lab.xml EX-101.LAB 17374
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE akba-20201210_pre.xml EX-101.PRE 10941
5 EXTRACTED XBRL INSTANCE DOCUMENT d33739d8k_htm.xml XML 3236
Mailing Address 245 FIRST STREET CAMBRIDGE MA 02142
Business Address 245 FIRST STREET CAMBRIDGE MA 02142 617-871-2098
Akebia Therapeutics, Inc. (Filer) CIK: 0001517022 (see all company filings)

IRS No.: 208756903 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36352 | Film No.: 201388250
SIC: 2834 Pharmaceutical Preparations